By Josée Rose
Teva Pharmaceutical Industries swung to a fourth-quarter loss on lower revenue and an operating loss.
Shares fell about 2.5% in premarket trading to $20.99.
The company swung to a fourth-quarter loss of $217 million, or 19 cents a share, compared with net income of $461 million, or 41 cents a share, a year earlier. Adjusted earnings were 71 cents a share compared with $1 a year earlier.
Revenue fell to $4.23 billion from $4.46 billion a year earlier. The company noted the exchange rate hurt overall revenue by $8 million in the quarter.
Analysts polled by Factset expected an adjusted profit of 71 cents a share and revenue of $4.15 billion.
Teva said its fourth-quarter operating loss was $29 million, compared to an operating income of $755 million a year earlier.
Teva said its generics business continued growing across the globe.
For 2025, the company expects adjusted earnings of $2.35 to $2.65 a share and revenue between $16.8 billion and $17.4 billion
Write to Josée Rose at josee.rose@wsj.com
(END) Dow Jones Newswires
January 29, 2025 08:41 ET (13:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.